Literature DB >> 15562089

Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia.

Eduardo N Chini1, Michael J Brown, Michael A Farrell, J William Charboneau.   

Abstract

Radiofrequency ablation (RFA) is an effective therapeutic intervention for a variety of neoplastic lesions. Many of these procedures are conducted with patients under general anesthesia. Although RFA is associated with infrequent complications, it is not without risk. Injury to adjacent normal structures is a major concern during RFA of cancerous lesions. Unintended injury to normal adrenal tissue during RFA of adrenal tumors can lead to hypertensive crisis, a potentially catastrophic complication. Hemodynamic consequences of RFA of primary or metastatic adrenal masses have not been reported. We report a case of hypertensive crisis (249/140 mm Hg), tachycardia, and ventricular arrhythmia in an 82-yr-old woman undergoing RFA of renal cell carcinoma metastatic to the adrenal gland. Anesthesiologists should be aware of this potentially catastrophic complication. Direct-acting vasodilators and short-acting beta(1)-adrenergic antagonists should be immediately available, and intraarterial blood pressure monitoring should be seriously considered when providing care for patients undergoing RFA of an adrenal mass.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562089     DOI: 10.1213/01.ANE.0000136803.54212.E1

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  17 in total

Review 1.  Percutaneous ablation of adrenal tumors.

Authors:  Aradhana M Venkatesan; Julia Locklin; Damian E Dupuy; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2010-06

2.  Cushing syndrome treated by radiofrequency ablation of adrenal gland adenoma.

Authors:  Naoko Nishi; Junji Tanaka; Akinobu Minagawa
Journal:  Jpn J Radiol       Date:  2012-01-25       Impact factor: 2.374

3.  Successful percutaneous radiofrequency ablation of adrenal metastasis from hepatocellular carcinoma.

Authors:  Hiroaki Haga; Takafumi Saito; Kazuo Okumoto; Kazuhiko Sugahara; Tadashi Takeda; Koji Saito; Hitoshi Togashi; Sumio Kawata
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

4.  Appropriate premedication risk reduction during adrenal ablation.

Authors:  Deepak Sudheendra; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2006-08       Impact factor: 3.464

5.  Anesthetic management for percutaneous computed tomography-guided radiofrequency ablation of reninoma: a case report.

Authors:  Nam-Su Gil; Jeong Yeol Han; Seong-Ho Ok; Il-Woo Shin; Heon Keun Lee; Young-Kyun Chung; Ju-Tae Sohn
Journal:  Korean J Anesthesiol       Date:  2015-01-28

6.  Complications of radiofrequency ablation of neoplasms.

Authors:  Albert A Nemcek
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 7.  Interventional radiology of the adrenal glands: current status.

Authors:  Anna Maria Ierardi; Mario Petrillo; Francesca Patella; Pierpaolo Biondetti; Enrico Maria Fumarola; Salvatore Alessio Angileri; Filippo Pesapane; Antonio Pinto; Gianlorenzo Dionigi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

8.  Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma.

Authors:  Min-Hsin Yang; Yeu-Sheng Tyan; Yu-Hui Huang; Shao-Chuan Wang; Sung-Lang Chen
Journal:  Radiol Med       Date:  2016-06-14       Impact factor: 3.469

9.  Contrast media-doped hydrodissection during thermal ablation: optimizing contrast media concentration for improved visibility on CT images.

Authors:  Calista Campbell; Meghan G Lubner; J Louis Hinshaw; Alejandro Muñoz del Rio; Christopher L Brace
Journal:  AJR Am J Roentgenol       Date:  2012-09       Impact factor: 3.959

10.  Radiofrequency ablation of metastatic pheochromocytoma.

Authors:  Aradhana M Venkatesan; Julia Locklin; Edwin W Lai; Karen T Adams; Antonio Tito Fojo; Karel Pacak; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2009-11       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.